WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC 50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > RIP kinase
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。